{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.66","value":"84.6"},{"groupId":"OG001","spread":"28.86","value":"80.3"},{"groupId":"OG002","spread":"16.33","value":"99.3"},{"groupId":"OG003","spread":"21.9","value":"90.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"7"}],"units":"Participants"}],"description":"Post-treatment neurocognitive function was assessed. Full-scale IQ (FSIQ) is a representative measurement for neurocognitive function. FSIQ was measured by IQ tests. Assessments within the time window, from eligible and evaluable patients are reported. The time window is 9+/-3 months post diagnosis, only the assessments before progression date were reported. The Range of FSIQ is 50-150. A higher FSIQ is better. Mean and standard deviation of FSIQ were calculated and reported.","dispersionType":"Standard Deviation","groups":[{"description":"SPNET patients who received regimen A (no carboplatin / no isotretinoin)","id":"OG000","title":"Regimen A (SPNET Patients)"},{"description":"SPNET patients who received regimen B (carboplatin / no isotretinoin)","id":"OG001","title":"Regimen B (SPNET Patients)"},{"description":"SPNET patients who received regimen C (no carboplatin / isotretinoin)","id":"OG002","title":"Regimen C (SPNET Patients)"},{"description":"SPNET patients who received regimen D (carboplatin / isotretinoin)","id":"OG003","title":"Regimen D (SPNET Patients)"}],"paramType":"MEAN","populationDescription":"Eligible SPNET patients are included.","reportingStatus":"POSTED","timeFrame":"6 - 12 months post diagnosis","title":"The Estimated Full-scale IQ (FSIQ) at 9+/-3 Months Post Diagnosis for SPNET Patients","type":"SECONDARY","unitOfMeasure":"Score on a scale"}